Analysts: Pfizer Inc (PFE)
PFE on New York Consolidated
28.93USD
20 May 2013
28.93USD
20 May 2013
Price Change (% chg)
$-0.03 (-0.10%)
$-0.03 (-0.10%)
Prev Close
$28.96
$28.96
Open
$28.97
$28.97
Day's High
$29.02
$29.02
Day's Low
$28.86
$28.86
Volume
9,808,871
9,808,871
Avg. Vol
32,213,001
32,213,001
52-wk High
$31.15
$31.15
52-wk Low
$21.40
$21.40
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.58 | December | 20 May 2013 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 9 | 10 | 10 | 11 |
| (2) OUTPERFORM | 6 | 6 | 6 | 5 |
| (3) HOLD | 4 | 4 | 4 | 4 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 1 | 1 | 1 | 1 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.90 | 1.86 | 1.86 | 1.81 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-13 | 11 | 14,218.50 | 14,571.00 | 13,938.00 | 15,097.50 |
| Quarter Ending Sep-13 | 11 | 13,813.30 | 14,245.00 | 13,323.00 | 15,363.00 |
| Year Ending Dec-13 | 14 | 56,471.20 | 57,328.00 | 55,345.00 | 59,651.70 |
| Year Ending Dec-14 | 17 | 55,649.70 | 58,145.00 | 50,995.00 | 59,118.50 |
| Earnings (per share) | |||||
| Quarter Ending Jun-13 | 13 | 0.58 | 0.61 | 0.55 | 0.55 |
| Quarter Ending Sep-13 | 13 | 0.56 | 0.57 | 0.53 | 0.60 |
| Year Ending Dec-13 | 17 | 2.21 | 2.29 | 2.16 | 2.34 |
| Year Ending Dec-14 | 19 | 2.35 | 2.49 | 2.19 | 2.44 |
| LT Growth Rate (%) | 4 | 2.80 | 4.00 | 0.60 | 2.48 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-13 | 13,988.80 | 13,500.00 | 488.77 | 3.49 |
| Quarter Ending Dec-12 | 14,379.70 | 15,068.00 | 688.27 | 4.79 |
| Quarter Ending Sep-12 | 14,638.50 | 13,976.00 | 662.48 | 4.53 |
| Quarter Ending Jun-12 | 14,865.50 | 15,057.00 | 191.46 | 1.29 |
| Quarter Ending Mar-12 | 15,469.00 | 15,405.00 | 64.01 | 0.41 |
| Earnings (per share) | ||||
| Quarter Ending Mar-13 | 0.55 | 0.54 | 0.01 | 2.69 |
| Quarter Ending Dec-12 | 0.44 | 0.47 | 0.03 | 6.21 |
| Quarter Ending Sep-12 | 0.52 | 0.53 | 0.00 | 0.95 |
| Quarter Ending Jun-12 | 0.54 | 0.62 | 0.08 | 14.20 |
| Quarter Ending Mar-12 | 0.56 | 0.58 | 0.02 | 2.93 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-13 | 14,218.50 | 14,294.90 | 14,397.40 | 14,508.80 | 15,097.50 |
| Quarter Ending Sep-13 | 13,813.30 | 13,858.80 | 13,929.50 | 14,036.10 | 15,363.00 |
| Year Ending Dec-13 | 56,471.20 | 56,723.50 | 57,242.00 | 57,643.60 | 59,651.70 |
| Year Ending Dec-14 | 55,649.70 | 55,710.80 | 56,522.50 | 56,578.40 | 59,118.50 |
| Earnings (per share) | |||||
| Quarter Ending Jun-13 | 0.58 | 0.58 | 0.59 | 0.59 | 0.55 |
| Quarter Ending Sep-13 | 0.56 | 0.55 | 0.57 | 0.57 | 0.60 |
| Quarter Ending Dec-13 | 2.21 | 2.23 | 2.28 | 2.28 | 2.34 |
| Quarter Ending Dec-14 | 2.35 | 2.35 | 2.38 | 2.36 | 2.44 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-13 | 0 | 1 | 1 | 8 |
| Quarter Ending Sep-13 | 0 | 1 | 1 | 8 |
| Year Ending Dec-13 | 0 | 1 | 1 | 12 |
| Year Ending Dec-14 | 0 | 0 | 0 | 10 |
| Earnings | ||||
| Quarter Ending Jun-13 | 0 | 0 | 1 | 10 |
| Quarter Ending Sep-13 | 0 | 0 | 1 | 11 |
| Year Ending Dec-13 | 0 | 0 | 1 | 16 |
| Year Ending Dec-14 | 1 | 0 | 2 | 10 |
Earnings vs. 
Estimates- Pfizer yet to decide on Pain Therapeutics' painkiller
- REUTERS SUMMIT-Drug industry CEOs plotting more carve-outs
- Pfizer results fall short; company trims profit forecast
- UPDATE 4-Pfizer results fall short; company trims profit forecast
- Pain Therapeutics, Durect shares soar on Pfizer's Remoxy comments
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (PFE). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
